Table 5 Duration of administration and dose intensity
From: Phase I trial of oral S-1 combined with gemcitabine in metastatic pancreatic cancer
No. of cycles | Cycles with dose reduction in gemcitabine | |||||
|---|---|---|---|---|---|---|
Dose level | S-1/gemcitabine (mg m−2) | No. of patients | Total | Median (range) | No. | % |
1 | 60/800 | 3 | 27 | 10 (3–14) | 5 | 19 |
2a | 80/800 | 6 | 66 | 7 (2–20) | 31 | 47 |
2b | 60/1000 | 12 | 61 | 4 (2–10) | 6 | 10 |
